EMA grants orphan designation to synthetic hypericin

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, granted orphan drug designation to synthetic hypericin, the active pharmaceutical ingredient in SGX301, for the treatment of cutaneous T-cell lymphoma, a rare disease and a class of non-Hodgkin’s lymphoma.

SGX301 has previously been granted both orphan drug and fast track designations from the FDA for the first-line treatment of CTCL.

Soligenix Inc., the drug’s sponsor, is currently working with leading CTCL centers, as well as with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation to begin a 120 subject pivotal phase III clinical trial with SGX301 in the second half of 2015.

SGX301 is a novel, first-in-class, photodynamic therapy utilizing visible light for activation. Synthetic hypericin is a potent photosensitizer which is topically applied to skin lesions and activated by visible fluorescent light.

In a phase II, double-blind, placebo-controlled clinical study in CTCL patients, the drug was safe and well tolerated, with 58.3 percent of the CTCL patients responding to SGX301 treatment compared to only 8.3 percent receiving placebo (p <= 0.04).

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login